These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 8879373)

  • 21. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.
    Reck M; von Pawel J; Macha HN; Kaukel E; Deppermann KM; Bonnet R; Ulm K; Hessler S; Gatzemeier U
    Lung Cancer; 2006 Jul; 53(1):67-75. PubMed ID: 16713013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
    Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
    Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
    Scheithauer W; Rosen H; Kornek GV; Sebesta C; Depisch D
    BMJ; 1993 Mar; 306(6880):752-5. PubMed ID: 7683942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
    Kajanti M; Pyrhönen S
    Am J Clin Oncol; 1994 Jun; 17(3):223-6. PubMed ID: 8192106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Van Hazel G; Blackwell A; Anderson J; Price D; Moroz P; Bower G; Cardaci G; Gray B
    J Surg Oncol; 2004 Nov; 88(2):78-85. PubMed ID: 15499601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
    Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
    Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group.
    Helsing M; Bergman B; Thaning L; Hero U
    Eur J Cancer; 1998 Jun; 34(7):1036-44. PubMed ID: 9849452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
    Macdonald JS; Jacobson JL; Modiano M; Moore DF; Gandara DR; Schroder LE; Chapman RA
    Invest New Drugs; 2000 Aug; 18(3):269-73. PubMed ID: 10958597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
    Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
    Abad A; Rosell R; Barnadas A; Carles J; Ribelles N; Solano V
    Ann Oncol; 1991 Feb; 2(2):153. PubMed ID: 2054318
    [No Abstract]   [Full Text] [Related]  

  • 32. Combined epirubicin, 5-fluorouracil and folinic acid vs no treatment for patients with advanced pancreatic cancer: a prospective comparative study.
    Tsavaris N; Tentas K; Tzivras M; Kosmas C; Kalachanis N; Katsikas M; Dimitrakopoulos A; Papastratis G; Macheras A; Karatzas G; Sechas M
    J Chemother; 1998 Aug; 10(4):331-7. PubMed ID: 9720474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Poon MA; O'Connell MJ; Moertel CG; Wieand HS; Cullinan SA; Everson LK; Krook JE; Mailliard JA; Laurie JA; Tschetter LK
    J Clin Oncol; 1989 Oct; 7(10):1407-18. PubMed ID: 2476530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.
    André T; Balosso J; Louvet C; Hannoun L; Houry S; Huguier M; Colonna M; Lotz JP; De Gramont A; Bellaïche A; Parc R; Touboul E; Izrael V
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):903-11. PubMed ID: 10705012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
    Taïeb J; Mitry E; Boige V; Artru P; Ezenfis J; Lecomte T; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Ann Oncol; 2002 Aug; 13(8):1192-6. PubMed ID: 12181241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.
    Carter R; Stocken DD; Ghaneh P; Bramhall SR; Olah A; Kelemen D; Bassi C; Friess H; Dervenis C; Spry N; Büchler MW; Neoptolemos JP;
    Int J Cancer; 2009 Jun; 124(12):2960-5. PubMed ID: 19330830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
    Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
    Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer.
    Sullivan KM; Kozuch PS
    Cancer J; 2012; 18(6):633-41. PubMed ID: 23187852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous and intra-arterial chemotherapeutic possibilities in biliopancreatic cancer.
    van Groeningen CJ
    Ann Oncol; 1999; 10 Suppl 4():305-7. PubMed ID: 10436846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.